fashion -WSS

fashion

author：leisure time 2025-10-01 02:28:04 - browse：2927

Eli Lilly headquarters — Kristoffer Tripplaar/AP

Eventually, the luckiest companies get to deal with a very particular problem: what to do when their stock could be getting ahead of itself.

It’s a problem Eli Lilly got a little taste of Tuesday when it announced its full-year earnings. The drugmaker’s stock has more than doubled over the past 12 months due to the ever-increasing hopes for its GLP-1-based diabetes and weight loss drug, sold under the brand names Mounjaro and Zepbound. It was a big deal when Lilly became the first drug company ever to have a market value of $500 billion; it’s now sitting at a stunning $670 billion.

At first, the earnings report suggested the company had blasted through expectations again, announcing fourth-quarter 2023 sales of $9.35 billion, almost half a billion dollars above analysts’ expectations, and also announcing new data for Mounjaro in treating metabolic dysfunction-associated steatohepatitis (MASH), a form of liver disease previously called NASH. Initially, shares traded up 5%.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： John Green on his newest strategy for fighting tuberculosis

Wikipedia

WSS

RaDonda Vaught links Vanderbilt hospital issues to patient death

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

Ebola: Gilead Sciences antiviral shows promise as new treatment

At ASCO, AstraZeneca reports strong data for breast cancer drug

Ultragenyx gene therapy for rare liver ailment succeeds in late

knowledge

fashion

hotspot

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

Alkermes shareholders re

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

Medical records are filled with copy

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

Cancer drug shortages should be causing more outrage

Boston's new lab space is opening empty

The high cost of giving birth even with insurance

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

focus

Amid AI frenzy, a top HHS official's quest to create safeguards

President Biden's budget: Here's what you might have missed

Innovation in antibiotics is ailing. 'Brain drain' may kill it

Change Healthcare outage fallout shows need for new oversight

Woman returns to dialysis after doctors remove transplanted pig kidney

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

Wikipedia

focus

knowledge

focus